DGX vs EHC
Quest Diagnostics Inc. and Encompass Health Corporation, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | DGX | EHC |
|---|---|---|
| Revenue | $11.0B | $5.9B |
| Net income | $992.0M | $566.2M |
| Gross margin | 33.2% | — |
| Net margin | 9.0% | 9.5% |
| Return on equity | 14.2% | 25.1% |
| Diluted EPS | $8.75 | $5.54 |
| Dividend / share | $1.80 | $0.72 |
| Payout ratio | 35.6% | 12.6% |
| Free cash flow | $1.4B | $439.2M |
| Equity | $7.2B | $2.4B |
| Net debt / equity | 0.73× | 0.97× |
| Current ratio | 1.04× | 1.08× |
| Revenue CAGR 5y | 3.2% | 10.7% |
| Profit CAGR 5y | −7.1% | 14.8% |
DGX bills 1.9× the revenue of EHC, and EHC keeps more of each dollar of revenue as profit (9.5% against 9.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | DGX | EHC |
|---|---|---|
| FY2025 | $11.0B | $5.9B |
| FY2024 | $9.9B | $5.4B |
| FY2023 | $9.3B | $4.8B |
| FY2022 | $9.9B | $4.3B |
| FY2021 | $10.8B | $4.0B |
| FY2020 | $9.4B | $3.6B |
| FY2019 | $7.7B | $4.6B |
| FY2018 | $7.5B | $4.3B |
| FY2017 | $7.4B | $3.9B |
| FY2016 | $7.2B | $3.6B |
Net income by year
Bottom line
| Fiscal year | DGX | EHC |
|---|---|---|
| FY2025 | $992.0M | $566.2M |
| FY2024 | $871.0M | $455.7M |
| FY2023 | $854.0M | $352.0M |
| FY2022 | $946.0M | $271.0M |
| FY2021 | $2.0B | $412.2M |
| FY2020 | $1.4B | $284.2M |
| FY2019 | $858.0M | $358.7M |
| FY2018 | $736.0M | $292.3M |
| FY2017 | $772.0M | $271.1M |
| FY2016 | $645.0M | $247.6M |
Advertisement
AdSense · Rectangle 336×280